Silexion Therapeutics Announces Groundbreaking Preclinical Results for SIL204, Demonstrating Near-Complete Inhibition of Pan-KRAS Mutations Across Multiple Cancer Types

Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company, announced new preclinical data for its investigational RNA interference (RNAi) therapy, SIL204. The findings, derived from studies in human cancer cell lines, confirm SIL204's activity as a pan-KRAS inhibitor, demonstrating inhibition rates between 83.5% and 99.7% across multiple KRAS mutations, including G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D. The company also reported first evidence of SIL204's activity in gastric cancer, in addition to expanded validation in colorectal cancer. These preclinical results are intended to support the company's plans to advance SIL204 into Phase 2/3 clinical trials, with regulatory submissions expected to the Israel Ministry of Health in the fourth quarter of 2025 and to the European Union in the first quarter of 2026. The results from these preclinical studies have been announced and will inform future clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003444), on September 30, 2025, and is solely responsible for the information contained therein.